0000000000022351

AUTHOR

Karim Iskander

showing 2 related works from this author

Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma

2020

Despite advances in standards of care, the prognosis of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) remains poor. In these patients, 50–74% fail to respond to next line therapy,...

OncologyCancer Researchmedicine.medical_specialty03 medical and health sciences0302 clinical medicineRefractoryimmune system diseaseshemic and lymphatic diseasesInternal medicineAntibodies BispecificmedicineHumansComplete responsebusiness.industryLymphoma Non-HodgkinHematologymedicine.diseaseLymphomaOncology030220 oncology & carcinogenesisRelapsed refractoryBlinatumomabLymphoma Large B-Cell DiffuseNeoplasm Recurrence LocalbusinessDiffuse large B-cell lymphoma030215 immunologymedicine.drugLeukemia & Lymphoma
researchProduct

Durability of complete response after blinatumomab therapy for refractory/relapsed aggressive B-cell non-Hodgkin lymphoma.

2019

e19041 Background: Achieving durable response in patients (pts) with relapsed/refractory (R/R) aggressive B-cell lymphoma (B-NHL) is challenging. Blinatumomab, a bispecific T-cell engager (BiTE) immunotherapy targeting CD19-expressing cancer cells, has shown promising efficacy in pts with R/R aggressive B-NHL. We report the durability of complete response (DOCR) in pts treated with blinatumomab. Methods: The DOCR in pts with R/R aggressive B-NHL responding to blinatumomab was assessed using data from two phase 2 studies (study 1 [N = 25], NCT01741792; study 2 [N = 41], NCT02910063) in pts with R/R aggressive B-NHL. CR was assessed using Cheson (study 1) and Lugano (study 2) criteria. Time-…

OncologyCancer Researchmedicine.medical_specialtybusiness.industryHematologyGeneral Medicinemedicine.diseaseLymphomaOncologyRefractoryimmune system diseaseshemic and lymphatic diseasesInternal medicinemedicineB-Cell Non-Hodgkin LymphomaBlinatumomabIn patientbusinessComplete responsemedicine.drugJournal of Clinical Oncology
researchProduct